Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: Lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature

Sarcoma

Volumn 2013, Issue , 2013, Pages

  O'Neill, Alison ^a   Shah, Nilay ^a   Zitomersky, Naamah ^b   Ladanyi, Marc ^c   Shukla, Neerav ^c   Üren, Aykut ^a   Loeb, David ^d   Toretsky, Jeffrey ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; CIXUTUMUMAB; FIGITUMUMAB; HISTIDINE; LIGAND; MONOCLONAL ANTIBODY; R 1507; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BIOTECHNOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; CELL POPULATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EWING SARCOMA; EWING SARCOMA STEM CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; LUMINEX TECHNOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SARCOMA CELL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL LINE;

EID: 84874547199     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2013/450478     Document Type: Article

References (46)

1. Grier H. E., Krailo M. D., Tarbell N. J., Link M. P., Fryer C. J. H., Pritchard D. J., Gebhardt M. C., Dickman P. S., Perlman E. J., Meyers P. A., Donaldson S. S., Moore S., Rausen A. R., Vietti T. J., Miser J. S., Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. The New England Journal of Medicine 2003 348 8 694 701 2-s2.0-0037456435 10.1056/NEJMoa020890 (Pubitemid 36237038)
2. Yee D., Favoni R. E., Lebovic G. S., Lombana F., Powell D. R., Reynolds C. P., Rosen N., Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. Journal of Clinical Investigation 1990 86 6 1806 1814 2-s2.0-0025632981
3. Toretsky J. A., Kalebic T., Blakesley V., LeRoith D., Helman L. J., The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. Journal of Biological Chemistry 1997 272 49 30822 30827 2-s2.0-0030695913 10.1074/jbc.272.49.30822 (Pubitemid 27527522)
4. Scotlandi K., Benini S., Nanni P., Lollini P. L., Nicoletti G., Landuzzi L., Serra M., Manara M. C., Picci P., Baldini N., Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Research 1998 58 18 4127 4131 2-s2.0-17744417798 (Pubitemid 28440569)
5. Benini S., Manara M. C., Baldini N., Cerisano V., Serra M., Mercuri M., Lollini P. L., Nanni P., Picci P., Scotlandi K., Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clinical Cancer Research 2001 7 6 1790 1797 2-s2.0-20244364227 (Pubitemid 32708650)
6. Scotlandi K., Maini C., Manara M. C., Benini S., Serra M., Cerisano V., Strammiello R., Baldini N., Lollini P. L., Nanni P., Nicoletti G., Picci P., Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Therapy 2002 9 3 296 307 2-s2.0-0036197370 10.1038/sj/cgt/7700442 (Pubitemid 34205505)
7. Scotlandi K., Manara M. C., Nicoletti G., Lollini P. L., Lukas S., Benini S., Croci S., Perdichizzi S., Zambelli D., Serra M., García- Echeverría C., Hofmann F., Picci P., Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Research 2005 65 9 3868 3876 2-s2.0-20944447905 10.1158/0008-5472.CAN-04-3192 (Pubitemid 40616368)
8. Manara M. C., Landuzzi L., Nanni P., Nicoletti G., Zambelli D., Lollini P. L., Nanni C., Hofmann F., García-Echeverría C., Picci P., Scotlandi K., Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clinical Cancer Research 2007 13 4 1322 1330 2-s2.0-33947262154 10.1158/1078-0432.CCR-06-1518 (Pubitemid 46424074)
9. Toretsky J. A., Steinberg S. M., Manjusha Thakar M. S., Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with ewing sarcoma family of tumors. Cancer 2001 92 11 2941 2947
10. Borinstein S. C., Barkauskas D. A., Krailo M., Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group. Cancer 2011 117 21 4966 4976
11. Scotlandi K., Manara M. C., Serra M., Marino M. T., Ventura S., Garofalo C., Alberghini M., Magagnoli G., Ferrari S., Lopez-Guerrero J. A., Llombard-Bosch A., Picci P., Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. European Journal of Cancer 2011 47 8 1258 1266 2-s2.0-79955541612 10.1016/j.ejca.2011.01. 007
12. Juergens H., Daw N. C., Geoerger B., Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. Journal of Clinical Oncology 2011 29 34 4534 4540
13. Pappo A. S., Patel S. R., Crowley J., R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. Journal of Clinical Oncology 2011 29 34 4541 4547
14. Malempati S., Weigel B., Ingle A. M., Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and ewing sarcoma: a report from the Children's Oncology Group. Journal of Clinical Oncology 2012 30 3 256 262
15. Lohrisch C., Piccart M., An overview of HER2. Seminars in Oncology 2001 28 6 3 11 2-s2.0-0035683625 (Pubitemid 34062043)
16. Sattler M., Mechanisms of transformation by the BCR/ABL oncogene. International Journal of Hematology 2001 73 3 278 291 2-s2.0-0035318564 (Pubitemid 33758984)
17. Scotlandi K., Benini S., Sarti M., Serra M., Lollini P. L., Maurici D., Picci P., Manara M. C., Baldini N., Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Research 1996 56 20 4570 4574 2-s2.0-0029838475 (Pubitemid 26338048)
18. Navarro S., Giraudo P., Karseladze A. I., Smirnov A., Petrovichev N., Savelov N., Alvarado-Cabrero I., Llombart-Bosch A., Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's Family of Tumors (EFT) and their therapeutic implications. Anticancer Research 2007 27 4 2457 2463 2-s2.0-34547762804 (Pubitemid 47228089)
19. Yang M., Zhang R., Yan M., Detection and characterization of side population in Ewing's sarcoma SK-ES-1 cells in vitro. Biochemical and Biophysical Research Communications 2010 39 1 1062 1066
20. Awad O., Yustein J. T., Shah P., Gul N., Katuri V., O'Neill A., Kong Y., Brown M. L., Toretsky J. A., Loeb D. M., High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-Fli1 inhibition. PLoS ONE 2010 5 11 2-s2.0-78649728590 10.1371/journal.pone. 0013943 e13943
21. Garofalo C., Manara M. C., Nicoletti G., Marino M. T., Lollini P. L., Astolfi A., Pandini G., López-Guerrero J. A., Schaefer K. L., Belfiore A., Picci P., Scotlandi K., Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011 30 24 2730 2740 2-s2.0-79958863370 10.1038/onc.2010.640
22. Sanchez G., Bittencourt D., Laud K., Barbier J., Delattre O., Auboeuf D., Dutertre M., Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proceedings of the National Academy of Sciences of the United States of America 2008 105 16 6004 6009 2-s2.0-43149105398 10.1073/pnas.0710748105 (Pubitemid 351758389)
23. De Alava E., Panizo A., Antonescu C. R., Huvos A. G., Pardo-Mindán F. J., Barr F. G., Ladanyi M., Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. American Journal of Pathology 2000 156 3 849 855 2-s2.0-0033870294 (Pubitemid 30626943)
24. Espositot D. L., Blakesley V. A., Koval A. P., Scrimgeour A. G., Leroith D., Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. Endocrinology 1997 138 7 2979 2988 2-s2.0-0030999592 10.1210/en.138.7.2979 (Pubitemid 27258532)
25. Institute W. T. S., Catalogue of Somatic Mutations in Cancer: IGF-1R. 2011, http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=gene&ln=IGF1R
26. Hamilton G., Mallinger R., Hofbauer S., Havel M., The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I. Thymus 1991 18 1 33 41 2-s2.0-0025911128
27. Hofbauer S., Hamilton G., Theyer G., Wollmann K., Gabor F., Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. European Journal of Cancer A 1993 29 2 241 245 2-s2.0-0027327920
28. Van Valen F., Winkelmann W., Jurgens H., Type I and Type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells. Journal of Cancer Research and Clinical Oncology 1992 118 4 269 275 2-s2.0-0026535686
29. Toretsky J. A., Thakar M., Eskenazi A. E., Frantz C. N., Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Research 1999 59 22 5745 5750 2-s2.0-0033571748
30. Scotlandi K., Avnet S., Benini S., Manara M. C., Serra M., Cerisano V., Perdichizzi S., Lollini P. L., De Giovanni C., Landuzzi L., Picci P., Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. International Journal of Cancer 2002 101 1 11 16 2-s2.0-0036722799 10.1002/ijc.10537 (Pubitemid 34832991)
31. Houghton P. J., Morton C. L., Tucker C., Payne D., Favours E., Cole C., Gorlick R., Kolb E. A., Zhang W., Lock R., Carol H., Tajbakhsh M., Reynolds C. P., Maris J. M., Courtright J., Keir S. T., Friedman H. S., Stopford C., Zeidner J., Wu J., Liu T., Billups C. A., Khan J., Ansher S., Zhang J., Smith M. A., The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood and Cancer 2007 49 7 928 940 2-s2.0-34447249881 10.1002/pbc.21078 (Pubitemid 350022448)
32. Anders Kolb E., Gorlick R., Houghton P. J., Morton C. L., Lock R., Carol H., Patrick Reynolds C., Maris J. M., Keir S. T., Billups C. A., Smith M. A., Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatric Blood and Cancer 2008 50 6 1190 1197 2-s2.0-42349083307 10.1002/pbc.21450 (Pubitemid 351555543)
33. Houghton P. J., Morton C. L., Gorlick R., Kolb E. A., Keir S. T., Reynolds C. P., Kang M. H., Maris J. M., Wu J., Smith M. A., Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. Pediatric Blood and Cancer 2010 54 7 921 926 2-s2.0-77951747892 10.1002/pbc.22367
34. Tao Y., Pinzi V., Bourhis J., Deutsch E., Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nature Clinical Practice Oncology 2007 4 10 591 602 2-s2.0-35148837581 10.1038/ncponc0934 (Pubitemid 47534758)
35. Prieur A., Tirode F., Cohen P., Delattre O., EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Molecular and Cellular Biology 2004 24 16 7275 7283 2-s2.0-3543026281 10.1128/MCB.24.16. 7275-7283.2004 (Pubitemid 39014452)
36. Ho A. L., Schwartz G. K., Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? Journal of Clinical Oncology 2011 29 34 4581 4583
37. Benini S., Manara M. C., Cerisano V., Perdichizzi S., Strammiello R., Serra M., Picci P., Scotlandi K., Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. International Journal of Cancer 2004 108 3 358 366 2-s2.0-0347626094 10.1002/ijc.11576 (Pubitemid 37549600)
38. Martins A. S., Mackintosh C., Herrero Martín D., Campos M., Hernández T., Ordóñez J. L., De Alava E., Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clinical Cancer Research 2006 12 11 3532 3540 2-s2.0-33745212417 10.1158/1078-0432.CCR-05-1778
39. Scotlandi K., Manara M. C., Hattinger C. M., Benini S., Perdichizzi S., Pasello M., Bacci G., Zanella L., Bertoni F., Picci P., Serra M., Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. European Journal of Cancer 2005 41 9 1349 1361 2-s2.0-20444501794 10.1016/j.ejca.2005.03.015 (Pubitemid 40813013)
40. Üren A., Merchant M. S., Sun C. J., Vitolo M. I., Sun Y., Tsokos M., Illei P. B., Ladanyi M., Passaniti A., Mackall C., Toretsky J. A., Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003 22 15 2334 2342 2-s2.0-0037994344 10.1038/sj.onc.1206330 (Pubitemid 36566788)
41. Girnita L., Girnita A., Wang M., Meis-Kindblom J. M., Kindblom L. G., Larsson O., A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells. Oncogene 2000 19 37 4298 4301 2-s2.0-0034738960
42. Shin D. H., Min H. Y., El-Naggar A. K., Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor i receptor monoclonal antibody. Molecular Cancer Therapeutics 2011 10 12 2437 2448
43. Kolb E. A., Gorlick R., Maris J. M., Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer, Pediatr Blood Cancer 2012 58 5 729 735 10.1002/pbc.23157
44. Kurmasheva R. T., Dudkin L., Billups C., Debelenko L. V., Morton C. L., Houghton P. J., The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Research 2009 69 19 7662 7671 10.1158/0008-5472.CAN-09-1693
45. Beltran P. J., Chung Y. A., Moody G., Mitchell P., Cajulis E., Vonderfecht S., Kendall R., Radinsky R., Calzone F. J., Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. Journal of Pharmacology and Experimental Therapeutics 2011 337 3 644 654 2-s2.0-79956205779 10.1124/jpet.110.178400
46. Naing A., P A. L., Fu S., Hong D. S., Anderson P., Benjamin P. S., Ludwig J., Chen H. X., Doyle L. A., Kurzrock R., Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory ewing's sarcoma family tumors. Clinical Cancer Research 2012 19 9 2625 2631